

Learner Notification

MED Learning Group

Graft Vs Host Disease: Novel Management Strategies for a Chronic Condition

June 16, 2023

Online

Acknowledgement of Financial Commercial Support

Sanofi

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Explain the evidence-based diagnostic criteria for chronic GVHD for prompt diagnosis.
2. Discuss the clinical safety and efficacy data of recently approved and investigational therapeutic agents.
3. Develop strategies to create treatment plans that include considerations for improvements in quality of life and psychosocial impact of disease.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Ana Maria	Albino	NA
Corey S.	Cutler	Omeros, CareDX, Mallinckrodt, Editas Medicine, Deciphera, Jazz, Incyte, Sanofi, Janssen, Bristol Myers Squibb, CTI BioPharma, Equillium, Jasper Therapeutics, CSL Behring: Consultant, Cimeio Therapeutics and Oxford Immune Algorithmics: Stock Shareholder
Daniel	DaSilva	NA
Jessica	Feygin	NA
Matthew	Frese	NA
Christina	Gallo	NA
Tara	Mayfield	NA
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com